Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (NCT04732871)
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Mobile, Alabama
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (46 Sites)
Showing the first 25 of 46 sites.
- GSK Investigational Site — Mobile, Alabama
- GSK Investigational Site — Phoenix, Arizona
- GSK Investigational Site — Riverside, California
- GSK Investigational Site — San Diego, California
- GSK Investigational Site — Coral Gables, Florida
- GSK Investigational Site — Fort Myers, Florida
- GSK Investigational Site — Sarasota, Florida
- GSK Investigational Site — The Villages, Florida
- GSK Investigational Site — Evansville, Indiana
- GSK Investigational Site — Wichita, Kansas
- GSK Investigational Site — Richfield, Minnesota
- GSK Investigational Site — Kansas City, Missouri
- GSK Investigational Site — Rochester, New York
- GSK Investigational Site — Mt. Pleasant, South Carolina
- GSK Investigational Site — Spartanburg, South Carolina
- GSK Investigational Site — San Antonio, Texas
- GSK Investigational Site — Norfolk, Virginia
- GSK Investigational Site — Wenatchee, Washington
- GSK Investigational Site — Espoo,
- GSK Investigational Site — Helsinki,
- GSK Investigational Site — Helsinki,
- GSK Investigational Site — Jarvenpaa,
- GSK Investigational Site — Kokkola,
- GSK Investigational Site — Oulu,
- GSK Investigational Site — Pori,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Respiratory Syncytial Virus Infections
- Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá — Bogotá,
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study — Birmingham, Alabama
- A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant — Lexington, Kentucky
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease — Los Angeles, California
- A Study of BLB-201 RSV Vaccine in Infants and Children — La Mesa, California
Explore by condition: All Respiratory Syncytial Virus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.